ChiCTR2100044519 版本V1.2 版本创建时间2021/09/12 23:45:33 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100044519 

最近更新日期:

Date of Last Refreshed on:

2021-09-12 23:45:17 

注册时间:

Date of Registration:

2021-03-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

高压氧治疗笑气滥用所致认知功能损害的对照研究临床研究

Public title:

Hyperbaric oxygen therapy for cognitive dysfunction induced by nitrous oxide abuse: an intervention-controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

高压氧治疗笑气滥用所致认知功能损害的对照研究临床研究

Scientific title:

Hyperbaric oxygen therapy for cognitive dysfunction induced by nitrous oxide abuse: an intervention-controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

罗丹 

研究负责人:

徐佳军 

Applicant:

Luo Dan 

Study leader:

Xu Jiajun 

申请注册联系人电话:

Applicant telephone:

+86 18380303847

研究负责人电话:

Study leader's
telephone:

+86 17381883373

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1028119746@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xujiajun120@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区电信南街28号

研究负责人通讯地址:

四川省成都市武侯区电信南街28号

Applicant address:

28 Dianxin Street South, Wuhou District, Chengdu, Sichuan

Study leader's address:

28 Dianxin Street South, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

Sichuan University West China Hospital

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

Sichuan University West China Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020年 审(1305)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Ethics Committee of West China Hospital of Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-01-27 00:00:00

伦理委员会联系人:

李娜

Contact Name of the ethic committee:

Li Na

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院心理卫生中心

Primary sponsor:

Mental Health Center, Sichuan University West China Hospital

研究实施负责(组长)单位地址:

四川省成都市武侯区电信南街28号

Primary sponsor's address:

28 Dianxin Street South, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

sichuan

City:

chengdu

单位(医院):

四川大学华西医院

具体地址:

武侯区国学巷37号

Institution
hospital:

Sichuan University West China Hospital

Address:

37 Guoxue Lane, Wuhou District

经费或物资来源:

相关课题结余经费

Source(s) of funding:

Relevant projects surplus funds

研究疾病:

笑气滥用所致认知功能损害  

Target disease:

cognitive function induced by nitrous oxide

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1. 主要目的:探讨高压氧治疗笑气滥用所致认知功能损害的有效性; 2. 次要目的:探讨笑气滥用所致认知功能损害的特征性改变。  

Objectives of Study:

Primary objective To evaluate the characteristic changes in cognitive impairment due to laughing gas abuse. Secondary objective To determine the effectiveness of HBOT for cognitive impairment induced by laughing gas abuse.

药物成份或治疗方案详述:

本研究是一项随机的病例对照研究,纳入符合入排标准的受试者,签署知情同意书后,进行临床资料的收集及基线认知功能的评估,评估后随机进行分组,分为干预组和对照组,对照组进行常规改善认知功能的治疗,干预组予以受试者高压氧治疗1个疗程(10次为1个疗程,每次90-120min,2个大气压下的空气加压舱内),治疗后评估受试者认知功能情况,探索笑气滥用后认知功能的特征性改变,比较对照组和干预组治疗前后的认知功能改变,探讨高压氧治疗对笑气滥用所致认知功能损害的有效性。 

Description for medicine or protocol of treatment in detail:

The study will be a prospective controlled before-and-after pilot intervention trial to evaluate the characteristic changes in cognitive impairment induced by nitrous oxide and the effect of HBOT for it comparing with control group via related cognitive assessments. The protocol conforms to the SPIRIT 2013 statement. 

纳入标准:

①有明确N2O接触史及短期频繁吸人史,符合DSM-5中物质使用障碍诊断标准的患者,年龄在18-60岁之间,男女均可;
②急性、亚急性或慢性起病,有明确的认知功能下降的症状,例如记忆力下降、定向力障碍、注意力下降、反应力变慢、学习能力减退等;
③自愿参加本研究,入组前向所有研究对象详细告知研究目的、方法以及可能的不适和风险,签署知情同意书。

Inclusion criteria

Patients with a clear history of N2O exposure, meeting the diagnostic criteria for substance abuse in DSM-5, who presents acute, subacute or chronic symptoms of cognitive decline, such as memory decline, disorientation, attention deficit, slower reaction, and learning disability will be eligible for inclusion.

排除标准:

①患有脑器质性疾病的患者;
②有除酒精及烟草以外的精神活性物质滥用者;
③有高压氧治疗禁忌的患者,如未处理的气胸、同时服用双硫仑类药物、同时服用抗肿瘤药物如博来霉素、顺铂、阿霉素;
④有高压氧治疗相对禁忌症的患者,如胸部外科手术围手术期、呼吸道传染性病毒感染、中耳手术围手术期、未控制的癫痫、高热、先天球形红细胞症、幽闭恐惧症、颅底骨折伴脑脊液漏、未控制的高血压、青光眼(闭角型)、肺大疱、心动过缓(<50次/min)、未处理的活动出血、结核空洞、严重肺气肿。
⑤不能排除其他原因引起的认知功能减退的患者。

Exclusion criteria:

Exclusion criteria include: Patients with organic brain diseases (eg, intracerebral hemorrhage, cerebral infarction), psychoactive substance abuse (in addition to alcohol, tobacco and caffeine), contraindications to hyperbaric oxygen therapy, other causes of cognitive decline.

研究实施时间:

Study execute time:

From 2021-03-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-03-23 00:00:00 To 2022-06-30 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

40

Group:

intervention group

Sample size:

干预措施:

高压氧治疗

干预措施代码:

Intervention:

Hyperbaric oxygen therapy

Intervention code:

组别:

对照组

样本量:

40

Group:

control group

Sample size:

干预措施:

一般治疗

干预措施代码:

Intervention:

general treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

Sichuan University West China Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

精神分裂症认知功能成套测验共识版

指标类型:

主要指标

Outcome:

MCCB

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉持续性注意测试

指标类型:

主要指标

Outcome:

VCPT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

听觉持续性注意测试

指标类型:

主要指标

Outcome:

ACPT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

威斯康星卡片分类测验

指标类型:

主要指标

Outcome:

WCST

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瑞文推理测验

指标类型:

主要指标

Outcome:

SPM

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Stroop色词测验

指标类型:

主要指标

Outcome:

CWT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

对试验中纳入的每一研究对象产生一个对应的随机数字;按照随机数字的由小到大的顺序进行排序;根据事先设定好的两个处理组样本量大小,按随机数字顺序选择相应的样本数量,分配到不同的处理组。

Randomization Procedure (please state who generates the random number sequence and by what method):

A corresponding random number is generated for each study subject included in the experiment; Sort the random numbers in order from smallest to largest; According to the pre-set sample sizes of the two treatment groups, the corresponding sample sizes will be selected in random number order.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

未说明 请阅读网页注册指南中关于“原始数据共享”的内容。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

未说明 请阅读网页注册指南中关于 数据收集和管理系统 的内容。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-03-23 01:29:27